NPH Neuropharm

 

TIDMNPH 
 
RNS Number : 9619J 
Neuropharm Group PLC 
09 April 2010 
 

 
+-------------------------------+-------------------------------+ 
| For Immediate Release         |                  9 April 2010 | 
+-------------------------------+-------------------------------+ 
 
 
 
                              Neuropharm Group Plc 
                        ("Neuropharm" or "the Company") 
 
 
                                  Board Change 
 
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on 
neurodevelopmental disorders, announces that Dr Mike Snape is stepping down from 
his position as Chief Scientific Officer and from the board of the Neuropharm 
Group with effect from 9th April.  The Board would like to thank Dr Snape for 
his considerable contribution as a founder of the Company and Chief Scientific 
Officer since its inception in 2005. 
 
 
For further information please contact: 
 
+----------------------------------------+--------------------------+ 
| Neuropharm                             | + 44 (0) 1372 371 171    | 
+----------------------------------------+--------------------------+ 
| Robert Mansfield, Chief Executive      |                          | 
| Officer                                |                          | 
| Graham Yeatman, Chief Financial        |                          | 
| Officer                                |                          | 
+----------------------------------------+--------------------------+ 
|                                        |                          | 
+----------------------------------------+--------------------------+ 
| Piper Jaffray Ltd.                     | + 44 (0) 20 3142 8700    | 
+----------------------------------------+--------------------------+ 
| Neil Mackison, Rupert Winckler         |                          | 
+----------------------------------------+--------------------------+ 
|                                        |                          | 
+----------------------------------------+--------------------------+ 
| Buchanan Communications                | + 44 (0) 20 7466 5000    | 
+----------------------------------------+--------------------------+ 
| Mark Court                             |                          | 
+----------------------------------------+--------------------------+ 
 
Notes to Editors: 
 
About Neuropharm 
Neuropharm is a speciality pharmaceutical company focused on the development of 
medicines for the treatment and management of neurodevelopmental disorders. 
Please visit www.neuropharm.co.uk for further information. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAKKCDQKBKDFQK 
 

Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024

Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024